Immunovant Inc. Common Stock vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.56 (market cap $2.03B). The key difference: Immunovant Inc. Common Stock is far larger — about 3.1× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| IMVT | TMF | |
|---|---|---|
Market Cap | $6.25B | $2.03B |
Volume | 1,755,411 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $44.96 | $44.14 |
52-Week Low | $17.03 | $25.19 |
Typical Hold Time | 0 Days | 28 Days |
Enterprise Value | $5.35B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.64 with a 1.61% daily gain amid elevated volume. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators are neutral. The ETF saw increased trading activity with over 5.2 million shares changing hands, as reported by Defense World on October 3, 2026. A dividend of $0.35 is scheduled for payment on September 29, 2026.
The outlook for TMF remains tied to long-term Treasury bond performance, with current technical weakness suggesting near-term pressure. Investment opportunity exists for investors bullish on declining long-term interest rates, but risks include interest rate volatility and the leveraged nature of the ETF amplifying losses. Market sentiment appears mixed given conflicting technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →